Dr. Parren will present preclinical data on LAVA’s lead solid tumor Gammabody™ LAVA-1207 as well as new non-human primate data supporting the safety and tolerability profile of LAVA’s lead solid tumor Gammabody™ programs.
Presenter: Paul W.H.I. Parren, Ph.D., Executive Vice President, Head of Research and Development
Presentation Title: Bispecific Gamma-Delta T Cell Engagers Targeting PSMA for the Treatment of Prostate Cancer
Location: San Diego and virtual – Sapphire Session Room
Stephen Hurly, President and Chief Executive Officer at LAVA Therapeutics, will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 12, 2022 at 10:30 a.m. EST.
Data Provided by Refinitiv. Minimum 15 minutes delayed.